RxDoctor Payments Data

Semaan El Khoury, MD

Internal Medicine · Aulander, NCNPI 1699749333

Payments from drug & device makers

$9,867in general payments, 2019–2025

Across 682 payments — averaging $14.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$1K
  • GSK$1K
  • Boehringer Ingelheim$629
  • Johnson & Johnson$624
  • Lilly USA, LLC$579
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$9,78899%
  • Education$781%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,867 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$327,093
Medicare patients
888
Services billed
6,774

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide241$304,534
EliquisApixaban399$232,543
MounjaroTirzepatide141$135,682
FarxigaDapagliflozin Propanediol161$134,236
TrulicityDulaglutide125$131,604
AbrysvoRsv Vacc, Pref A And Pref B/Pf385$123,636
JardianceEmpagliflozin144$117,566
JanuviaSitagliptin Phosphate182$106,101
XareltoRivaroxaban157$100,808
Trelegy ElliptaFluticasone/Umeclidin/Vilanter92$82,470
LinzessLinaclotide76$63,135
TradjentaLinagliptin66$61,831
RybelsusSemaglutide22$44,704
MyrbetriqMirabegron56$39,782
Tresiba Flextouch U-100Insulin Degludec70$36,546

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$573$356,178784 claims
Novo NordiskOzempic, Rybelsus$1,135$349,238263 claims
Lilly USA, LLCMounjaro, Trulicity$579$267,286266 claims
Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Spiriva Respimat$629$214,644251 claims
AstraZenecaFarxiga, Symbicort, Lokelma, Breztri Aerosphere$1,389$175,312266 claims
GSKTrelegy Ellipta, Shingrix, Arexvy, Breo Ellipta$1,104$140,214307 claims
MerckJanuvia, Janumet Xr$167$131,342208 claims
Johnson & JohnsonXarelto$624$100,808157 claims
AbbVieLinzess, Vraylar$363$77,47396 claims
Astellas Pharma US IncMyrbetriq$111$39,78256 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$158$15,68123 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$220$9,71911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Aulander

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →